- Ultragenyx Pharmaceutical Inc at Cowen Health Care Conference- Orphan CNS Panel Discussion TranscriptMar 07, 2023
- AVROBIO Inc Virtual Gaucher Disease Program Update TranscriptDec 07, 2022
- AVROBIO Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2022
- AVROBIO Inc at Needham Healthcare Conference (Virtual) TranscriptApr 12, 2022
- AVROBIO Inc at Barclays Global Healthcare Conference TranscriptMar 15, 2022
- Ultragenyx Pharmaceutical Inc, Alector Inc, Passage Bio Inc, AVROBIO Inc and Annexon Inc in the Orphan CNS Panel at Cowen Health Care Conference (Virtual) TranscriptMar 08, 2022
- AVROBIO Inc Cystinosis Update Call TranscriptFeb 09, 2022
- AVROBIO Inc at Barclays Gene Editing & Gene Therapy Summit (Virtual) TranscriptNov 15, 2021
- AVROBIO Inc at Jefferies Gene Therapy/Editing Summit (Virtual) TranscriptOct 28, 2021
- AVROBIO Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 14, 2021
- AVROBIO Inc at JMP Securities Life Sciences Virtual Conference TranscriptJun 17, 2021
- AVROBIO Inc at Barclays Global Healthcare Conference (Virtual) TranscriptMar 09, 2021
- AVROBIO Inc Presents new Clinical Data from Fabry Disease, Cystinosis and Gaucher disease Type 1 Programs TranscriptFeb 08, 2021
- AVROBIO Inc at ICR Virtual Conference TranscriptJan 14, 2021
- AVROBIO Inc Virtual R&D Day TranscriptNov 17, 2020
- AVROBIO Inc at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa (Virtual) TranscriptOct 13, 2020
- AVROBIO Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 14, 2020
- Avrobio Inc at WORLDSymposium 2020 TranscriptFeb 11, 2020
- AVROBIO Inc Announces Positive Data from Clinical Trials of AVR-RD-01- Call TranscriptJul 15, 2019
AVROBIO Inc at Barclays Global Healthcare Conference Transcript
Hello. Can you address the timer properly? Okay, good. Are we live now? Okay. Great. Thank you. Good afternoon, everyone. My name is Gena Wang. I'm the [SMID-cap] biotech analyst. It is my great pleasure to introduce our next presenting company, AVROBIO. With us today, we have Geoff MacKay, President and CEO.
Thank you, Gena. So my name is Geoff MacKay, and I'll sum up my company, AVROBIO. Before I begin, of course, we'll be making forward-looking statements based on current expectations and beliefs, so I point you to our SEC filings.
The goal of AVROBIO is to free patients from a lifetime of disease, and for us, that means a one-time single infusion of gene therapy targeting multiple serious genetic -- monogenetic diseases. And our goal is to develop global therapies.
Some real top line points before I jump into the data is that we -- our particular brand of gene therapy is hematopoietic stem cells
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)